GC
OPRX icon

Guggenheim Capital’s OptimizeRx OPRX Stock Holding History

Guggenheim Capital’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,534
Closed -$234K – 2007
2022
Q2 		$234K Buy
+8,534
New +$253K ﹤0.01% 1884
2022
Q1 		– Sell
-4,319
Closed -$268K – 2168
2021
Q4 		$268K Buy
+4,319
New +$327K ﹤0.01% 1929

Other funds holding OPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Guggenheim Capital's OPRX Position: Q3 2022 in Review

Guggenheim Capital sold out of OptimizeRx (OPRX) in Q3 2022, closing a stake of 8,534 shares — an estimated $234K sold.

Guggenheim Capital first reported a position in OPRX in Q4 2021 and held it in 2 quarters. The position peaked at $268K in Q4 2021. 128 funds tracked by Wall St. Rank hold OPRX as of Q3 2022.

  • Guggenheim Capital reported no remaining OptimizeRx position as of Q3 2022 after selling out during the quarter.
  • Guggenheim Capital sold 8,534 OptimizeRx shares in Q3 2022, an estimated $234K.
  • Guggenheim Capital first reported a position in OptimizeRx in Q4 2021 and held it in 2 quarters.
  • Guggenheim Capital's OptimizeRx position peaked at $268K in Q4 2021.
  • 128 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2022.

Based on Guggenheim Capital's 13F filing for Q3 2022, filed 14 Nov 2022.